Log In
BCIQ
Print this Print this
 

Relday, risperidone (ZX003)

  Manage Alerts
Collapse Summary General Information
Company Durect Corp.
DescriptionDosePro subcutaneous drug delivery system plus a subcutaneous once-monthly formulation of risperidone formulated using Durect's SABER controlled-release technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia
Regulatory Designation
PartnerZogenix Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$105.3M

$2.3M

$103.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/18/2011

$105.3M

$2.3M

$103.0M

Get a free BioCentury trial today